// App-Quantinova.ai

420 : Translational strategy for targeting MCL1 amplified tumors with CDK9 inhibitor

Researchers

Presenter

  • Ziping Yang

Principal Investigators

  • Ricky Bellin

  • Paul Hessler

  • Xin Lu

  • Tamar Uziel

  • Lloyd T. Lam

Medical Centers

  • AbbVie, Inc., North Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Triple-negative breast cancer

  • Non Small Cell Lung cancer

  • Small cell lung cancer

  • Colorectal Cancer

  • B cell lymphomas

  • Solid malignancies

  • Breast cancer

  • Lung Cancer

  • Lymphomas

Biomarkers

  • Myeloid Cell Leukemia 1

  • B-cell lymphoma 2

  • B-cell lymphoma-extra large

Drug/Treatment

  • Dinaciclib

  • Navitoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved